MX2010004830A - Compuestos de 1,2,4, -triazin- 3,5-diona para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3. - Google Patents
Compuestos de 1,2,4, -triazin- 3,5-diona para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3.Info
- Publication number
- MX2010004830A MX2010004830A MX2010004830A MX2010004830A MX2010004830A MX 2010004830 A MX2010004830 A MX 2010004830A MX 2010004830 A MX2010004830 A MX 2010004830A MX 2010004830 A MX2010004830 A MX 2010004830A MX 2010004830 A MX2010004830 A MX 2010004830A
- Authority
- MX
- Mexico
- Prior art keywords
- c3alkyl
- fluorinated
- dopamine
- formula
- respond
- Prior art date
Links
- 102000004073 Dopamine D3 Receptors Human genes 0.000 title 1
- 108090000525 Dopamine D3 Receptors Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 229940088353 Dopamine D3 receptor antagonist Drugs 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229930195734 saturated hydrocarbon Natural products 0.000 abstract 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a compuestos de la fórmula (I), en donde A es una cadena de hidrocarburo saturada o insaturada que tiene una longitud de cadena de 4 a 6 átomos de carbono, la cadena de hidrocarburo estando no substituida o substituida por 1, 2 ó 3 grupos metilo; R1 se selecciona del grupo que consiste de hidrógeno, alquilo de 1 a 3 átomos de carbono y alquilo de 1 a 3 átomos de carbono fluorado; R2 es hidrógeno, halógeno, ciano, alquilo de 1 a 3 átomos de carbono, alcoxi de 1 a 3 átomos de carbono, alquilo de 1 a 3 átomos de carbono fluorado o alcoxi de 1 a 3 átomos de carbono fluorado; R3 se selecciona del grupo que consiste de alquilo de 4 a 6 átomos de carbono y cicloalquilo de 3 a 6 átomos de carbono; y R4 es alquilo de 1 a 6 átomos de carbono, cicloalquilo de 3 a 6 átomos de carbono, alquilo de 1 a 3 átomos de carbono fluorado y cicloalquilo de 3 a 6 átomos de carbono fluorado, y sales fisiológicamente toleradas de estos compuestos y sus N-óxidos. La invención también se refiere a una composición farmacéutica que comprende por lo menos un compuesto de la fórmula (I) y/o por lo menos una sal de adición de ácido fisiológicamente tolerado del mismo, y además un método para tratar trastornos que responden benéficamente a antagonistas del receptor de dopamina D3 o agonistas de dopamina D3, dicho método comprende administrar una cantidad efectiva de por lo menos un compuesto o sal de adición de ácido fisiológicamente tolerada de la fórmula (I) a un sujeto con la necesidad del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07119927 | 2007-11-02 | ||
| PCT/EP2008/064795 WO2009056625A1 (en) | 2007-11-02 | 2008-10-31 | 1,2,4,-triazin-3,5-dione compounds for treating disorders that respond to modulation of the dopamine d3 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010004830A true MX2010004830A (es) | 2010-10-20 |
Family
ID=40210491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010004830A MX2010004830A (es) | 2007-11-02 | 2008-10-31 | Compuestos de 1,2,4, -triazin- 3,5-diona para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US8492540B2 (es) |
| EP (1) | EP2217593B1 (es) |
| JP (1) | JP5559694B2 (es) |
| KR (1) | KR20100094491A (es) |
| CN (1) | CN101932574B (es) |
| AR (1) | AR069150A1 (es) |
| AT (1) | ATE556069T1 (es) |
| AU (1) | AU2008320814B2 (es) |
| BR (1) | BRPI0818726A2 (es) |
| CA (1) | CA2704533C (es) |
| CL (1) | CL2008003253A1 (es) |
| CO (1) | CO6280473A2 (es) |
| CR (1) | CR11410A (es) |
| DO (1) | DOP2010000126A (es) |
| EC (1) | ECSP10010227A (es) |
| ES (1) | ES2386691T3 (es) |
| HK (1) | HK1146628A1 (es) |
| IL (1) | IL205468A0 (es) |
| MX (1) | MX2010004830A (es) |
| MY (1) | MY154066A (es) |
| NZ (1) | NZ585051A (es) |
| PA (1) | PA8802101A1 (es) |
| PE (1) | PE20090950A1 (es) |
| RU (1) | RU2478633C2 (es) |
| TW (1) | TWI463984B (es) |
| UA (1) | UA99634C2 (es) |
| UY (1) | UY31448A1 (es) |
| WO (1) | WO2009056625A1 (es) |
| ZA (1) | ZA201003593B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9505753B2 (en) | 2012-08-08 | 2016-11-29 | The Johns Hopkins University | Inhibitors of D-amino acid oxidase |
| US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
| AR095264A1 (es) | 2013-03-15 | 2015-09-30 | Abbvie Deutschland | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
| UY35420A (es) | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
| KR102643833B1 (ko) | 2022-06-30 | 2024-03-06 | 현대제철 주식회사 | 이강종 연연주시 강종 예측 정합성 증대 방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4425144A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Triazolverbindungen und deren Verwendung |
| DE4425143A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Substituierte Pyrimidinverbindungen und deren Verwendung |
| DE4425146A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Verwendung heterocyclischer Verbindungen |
| FR2727682A1 (fr) | 1994-12-02 | 1996-06-07 | Pf Medicament | Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament |
| DE19728996A1 (de) | 1997-07-07 | 1999-01-14 | Basf Ag | Triazolverbindungen und deren Verwendung |
| FR2769913B1 (fr) * | 1997-10-16 | 2000-03-10 | Pf Medicament | Nouveaux derives cyclohexaniques difonctionnalises en 1, 4, leur preparation et leur application therapeutique humaine |
| DE10311065A1 (de) | 2003-03-13 | 2004-09-23 | Abbott Gmbh & Co. Kg | Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung |
| JP2004359689A (ja) * | 2003-06-05 | 2004-12-24 | Abbott Gmbh & Co Kg | ドーパミンｄ３受容体のモジュレーションに反応する障害の治療に適するトリアゾール化合物 |
| DE102004027358A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyrimidinverbindungen und ihre Verwendung |
| DE102004027359A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyridin-2-onverbindungen und deren Verwendung |
| ATE452134T1 (de) * | 2004-08-09 | 2010-01-15 | Abbott Gmbh & Co Kg | Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen |
| US8101754B2 (en) * | 2004-12-02 | 2012-01-24 | Abbott Gmbh & Co. Kg | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
| DE102004061593A1 (de) * | 2004-12-21 | 2006-06-22 | Abbott Gmbh & Co. Kg | Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung |
| EP2548874A3 (en) * | 2007-06-28 | 2013-05-15 | Intervet International B.V. | Substituted piperazines as CB1 antagonists |
-
2008
- 2008-10-29 PA PA20088802101A patent/PA8802101A1/es unknown
- 2008-10-30 CL CL2008003253A patent/CL2008003253A1/es unknown
- 2008-10-30 TW TW097141858A patent/TWI463984B/zh not_active IP Right Cessation
- 2008-10-31 CA CA2704533A patent/CA2704533C/en not_active Expired - Fee Related
- 2008-10-31 UY UY31448A patent/UY31448A1/es not_active Application Discontinuation
- 2008-10-31 AR ARP080104789A patent/AR069150A1/es unknown
- 2008-10-31 MY MYPI2010001969A patent/MY154066A/en unknown
- 2008-10-31 RU RU2010122337/04A patent/RU2478633C2/ru not_active IP Right Cessation
- 2008-10-31 MX MX2010004830A patent/MX2010004830A/es active IP Right Grant
- 2008-10-31 WO PCT/EP2008/064795 patent/WO2009056625A1/en active Application Filing
- 2008-10-31 NZ NZ585051A patent/NZ585051A/en not_active IP Right Cessation
- 2008-10-31 BR BRPI0818726 patent/BRPI0818726A2/pt not_active IP Right Cessation
- 2008-10-31 AT AT08844723T patent/ATE556069T1/de active
- 2008-10-31 PE PE2008001865A patent/PE20090950A1/es not_active Application Discontinuation
- 2008-10-31 EP EP08844723A patent/EP2217593B1/en active Active
- 2008-10-31 CN CN200880124247.7A patent/CN101932574B/zh not_active Expired - Fee Related
- 2008-10-31 ES ES08844723T patent/ES2386691T3/es active Active
- 2008-10-31 JP JP2010531532A patent/JP5559694B2/ja not_active Expired - Fee Related
- 2008-10-31 UA UAA201006793A patent/UA99634C2/ru unknown
- 2008-10-31 AU AU2008320814A patent/AU2008320814B2/en not_active Ceased
- 2008-10-31 KR KR1020107011975A patent/KR20100094491A/ko not_active Application Discontinuation
- 2008-10-31 US US12/740,714 patent/US8492540B2/en active Active
-
2010
- 2010-04-29 DO DO2010000126A patent/DOP2010000126A/es unknown
- 2010-04-29 IL IL205468A patent/IL205468A0/en unknown
- 2010-05-03 CR CR11410A patent/CR11410A/es unknown
- 2010-05-20 ZA ZA2010/03593A patent/ZA201003593B/en unknown
- 2010-06-01 EC EC2010010227A patent/ECSP10010227A/es unknown
- 2010-06-01 CO CO10065792A patent/CO6280473A2/es active IP Right Grant
-
2011
- 2011-01-25 HK HK11100717.9A patent/HK1146628A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008076243A3 (en) | Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment | |
| PH12013500848B1 (en) | Trpv1 antagonists and uses thereof | |
| MX2007012936A (es) | Derivados de dihidrobenzofurano y usos de los mismos. | |
| WO2007129195A3 (en) | 4-pyrimidine-5-amino-pyrazole compounds | |
| WO2006119507A3 (en) | Non-nucleotide composition and method for inhibiting platelet aggregation | |
| UA101601C2 (uk) | Інгібітори амідогідролази жирних кислот | |
| WO2008019967A3 (en) | Phenyl, pyridine and quinoline derivatives | |
| BRPI0510365A (pt) | composto, método de produção de um composto, antagonista do receptor nk2, pró-droga, agente farmacêutico, métodos para antagonizar um recpetor nk2 e para evitar ou tratar doenças gastrintestinais funcionais, e, uso do composto ou uma pró-droga do mesmo | |
| WO2005097814A3 (en) | Composition and method for inhibiting platelet aggregation | |
| UA96308C2 (ru) | Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение | |
| MX2010004830A (es) | Compuestos de 1,2,4, -triazin- 3,5-diona para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3. | |
| MY141024A (en) | Niacin receptor agonists, compositions containing such compounds and methods of treatment | |
| UY29212A1 (es) | Azabenzoxazoles para el tratamiento de trastornos del snc | |
| WO2009061374A3 (en) | Deuterated fingolimod | |
| WO2008157404A3 (en) | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators | |
| DE602004027409D1 (de) | Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation | |
| MX2009010630A (es) | Derivados de azabicicloalcano selectivos de sub-tipo. | |
| EA200901391A1 (ru) | Пиримидинилпиперазины, применимые в качестве лигандов рецепторов d/d | |
| TW200633710A (en) | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | |
| MX2009012518A (es) | Derivados de piperidina 4,4-disubstituidos. | |
| MX2010004300A (es) | Ligandos de (1,4-diaza-biciclo [3,2,2]non-6-en-4-il)-heterociclil- metanona para receptores nicotinicos de acetilcolina, utiles para el tratamiento de enfermedad. | |
| MX2009008777A (es) | Derivados y analogos de cromano como agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos. | |
| MY146992A (en) | Sulfonyl-quinoline derivatives | |
| MX2009005242A (es) | Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo. | |
| WO2010045582A3 (en) | Compositions and methods for treating or preventing hypoxic or ischemic injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| GB | Transfer or rights |